Lumos Diagnostics Holdings (ASX:LDX) FCF Margin % : -175.34% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Lumos Diagnostics Holdings's Free Cash Flow for the six months ended in Dec. 2023 was A$-7.25 Mil. Lumos Diagnostics Holdings's Revenue for the six months ended in Dec. 2023 was A$4.13 Mil. Therefore, Lumos Diagnostics Holdings's FCF Margin % for the quarter that ended in Dec. 2023 was -175.34%.

As of today, Lumos Diagnostics Holdings's current FCF Yield % is -74.83%.

The historical rank and industry rank for Lumos Diagnostics Holdings's FCF Margin % or its related term are showing as below:

ASX:LDX' s FCF Margin % Range Over the Past 10 Years
Min: -192.53 Med: -142.75 Max: -92.96
Current: -105.84

During the past 2 years, the highest FCF Margin % of Lumos Diagnostics Holdings was -92.96%. The lowest was -192.53%. And the median was -142.75%.

ASX:LDX's FCF Margin % is ranked worse than
78.38% of 222 companies
in the Medical Diagnostics & Research industry
Industry Median: -12.715 vs ASX:LDX: -105.84

Lumos Diagnostics Holdings FCF Margin % Historical Data

The historical data trend for Lumos Diagnostics Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings FCF Margin % Chart

Lumos Diagnostics Holdings Annual Data

Trend

Jun22

Jun23

FCF Margin %

-192.53

-92.96

Lumos Diagnostics Holdings Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial			-258.69	-160.79	-117.04	-70.46	-175.34

Competitive Comparison of Lumos Diagnostics Holdings's FCF Margin %

For the Diagnostics & Research subindustry, Lumos Diagnostics Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumos Diagnostics Holdings's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Lumos Diagnostics Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Lumos Diagnostics Holdings's FCF Margin % falls into.

Lumos Diagnostics Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Lumos Diagnostics Holdings's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-14.592	/	15.697
	=	-92.96 %

Lumos Diagnostics Holdings's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-7.245	/	4.132
	=	-175.34 %

Lumos Diagnostics Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Diagnostics Holdings (ASX:LDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

LDXHF:USA

Address

2724 Loker Ave West, Carlsbad, CA, USA, 92010

Website

https://www.lumosdiagnostics.com

Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. It also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases. It generates maximum revenue from the commercial services and solutions relating to POC diagnostic tests.

Lumos Diagnostics Holdings (ASX:LDX) Headlines

No Headlines